Stringent doxycycline-dependent control of gene activities using an episomal one-vector system -: art. no. e137

被引:118
作者
Bornkamm, GW
Berens, C
Kuklik-Roos, C
Bechet, JM
Laux, G
Bachl, J
Korndoerfer, M
Schlee, M
Hölzel, M
Malamoussi, A
Chapman, RD
Nimmerjahn, F
Mautner, J
Hillen, W
Bujard, H
Feuillard, J
机构
[1] GSF, Inst Klin Mol Biol & Tumor Genet, D-81377 Munich, Germany
[2] Univ Erlangen Nurnberg, Lehrstuhl Mikrobiol, D-91058 Erlangen, Germany
[3] Univ Caen, UMR 6551, F-14074 Caen, France
[4] Tech Univ Munich, Kinderklin, Klin Kooperat Grp Padist Tumor Immunol, D-8000 Munich, Germany
[5] Univ Heidelberg, Zentrum Mol Biol, D-69120 Heidelberg, Germany
[6] CHU Dupuytren, UMR 6101, CNRS, Fac Med Limoges, F-87042 Limoges, France
[7] CHU Dupuytren, Hematol Lab, F-87042 Limoges, France
关键词
D O I
10.1093/nar/gni137
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Conditional expression systems are of pivotal importance for the dissection of complex biological phenomena. Here, we describe a novel EBV-derived episomally replicating plasmid (pRTS-1) that carries all the elements for conditional expression of a gene of interest via Tet regulation. The vector is characterized by (i) low background activity, (ii) high inducibility in the presence of doxycycline (Dox) and (iii) graded response to increasing concentrations of the inducer. The chicken beta actin promoter and an element of the murine immunoglobin heavy chain intron enhancer drive constitutive expression of a bicistronic expression cassette that encodes the highly Dox-sensitive reverse tetracycline controlled transactivator rtTA2(S)-M2 and a Tet repressor-KRAB fusion protein (tTS(KRAB)) (silencer) placed downstream of an internal ribosomal entry site. The gene of interest is expressed from the bidirectional promoter P(tet)bi-1 that allows simultaneous expression of two genes, of which one may be used as surrogate marker for the expression of the gene of interest. Tight down regulation is achieved through binding of the silencer tTS(KRAB) to P(tet)bi-1 in the absence of Dox. Addition of Dox releases repression and via binding of rtTA2(S)-M2 activates P(tet)bi-1.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 36 条
[1]   Regulated recruitment of HP1 to a euchromatic gene induces mitotically heritable, epigenetic gene silencing: a mammalian cell culture model of gene variegation [J].
Ayyanathan, K ;
Lechner, MS ;
Bell, P ;
Maul, GG ;
Schultz, DC ;
Yamada, Y ;
Tanaka, K ;
Torigoe, K ;
Rauscher, FJ .
GENES & DEVELOPMENT, 2003, 17 (15) :1855-1869
[2]   Tet repressor-based system for regulated gene expression in eukaryotic cells: Principles and advances [J].
Baron, U ;
Bujard, H .
APPLICATIONS OF CHIMERIC GENES AND HYBRID PROTEINS PT B: CELL BIOLOGY AND PHYSIOLOGY, 2000, 327 :401-421
[3]   Generation of conditional mutants in higher eukaryotes by switching between the expression of two genes [J].
Baron, U ;
Schnappinger, D ;
Helbl, V ;
Gossen, M ;
Hillen, W ;
Bujard, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (03) :1013-1018
[4]   COREGULATION OF 2 GENE ACTIVITIES BY TETRACYCLINE VIA A BIDIRECTIONAL PROMOTER [J].
BARON, U ;
FREUNDLIEB, S ;
GOSSEN, M ;
BUJARD, H .
NUCLEIC ACIDS RESEARCH, 1995, 23 (17) :3605-3606
[5]  
BERGER S, 2003, HDB EXPT PHARM
[6]   Improving stable transfection efficiency:: antioxidants dramatically improve the outgrowth of clones under dominant marker selection [J].
Brielmeier, M ;
Béchet, JM ;
Falk, MH ;
Pawlita, M ;
Polack, A ;
Bornkamm, GW .
NUCLEIC ACIDS RESEARCH, 1998, 26 (09) :2082-2085
[7]   Analysis of different promoter systems for efficient transgene expression in mouse embryonic stem cell lines [J].
Chung, SM ;
Andersson, T ;
Sonntag, KC ;
Björklund, L ;
Isacson, O ;
Kim, KS .
STEM CELLS, 2002, 20 (02) :139-145
[8]   Latent membrane protein 1 of Epstein-Barr virus induces CD83 by the NF-κB signaling pathway [J].
Dudziak, D ;
Kieser, A ;
Dirmeier, U ;
Nimmerjahn, F ;
Berchtold, S ;
Steinkasserer, A ;
Marschall, G ;
Hammerschmidt, W ;
Laux, G ;
Bornkamm, GW .
JOURNAL OF VIROLOGY, 2003, 77 (15) :8290-8298
[9]  
FalK MH, 1998, INT J CANCER, V75, P620, DOI 10.1002/(SICI)1097-0215(19980209)75:4<620::AID-IJC21>3.0.CO
[10]  
2-B